Abstract: (1) Background: Pneumocystis jirovecii pneumonia (PCP) has a substantial impact on the morbidity and mortality of patients, especially those with autoimmune disorders, thus requiring optimal dosing strategies of Trimethoprim–Sulfamethoxazole (TMP-SMX). Therefore, to ensure the safety of TMP-SMX, there is a high demand to review current evidence in PCP patients with a focus on dose optimization strategies; (2) Methods: Various databases were searched from January 2000 to December 2021 for articles in English, focusing on the dose optimization of TMP-SMX. The data were collected in a specific form with predefined inclusion and exclusion criteria. The quality of each study was evaluated using a Newcastle–Ottawa Scale (NOS) for retrospective studies, Joanna Briggs Institute (JBI) critical checklist for case reports, and Cochrane bias tool for randomized clinical trials (RCTs); (3) Results: Thirteen studies met the inclusion criteria for final analysis. Of the 13 selected studies, nine were retrospective cohort studies, two case reports, and two randomized controlled trials (RCT). Most of the studies compared the high-dose with low-dose TMP-SMX therapy for PCP. We have found that a low dose of TMP-SMX provides satisfactory outcomes while reducing the mortality rate and PCP-associated adverse events. This strategy reduces the economic burden of illness and enhances patients’ compliance to daily regimen plan; (4) Conclusions: The large-scale RCTs and cohort studies are required to improve dosing strategies to prevent initial occurrence of PCP or to prevent recurrence of PCP in immune compromised patients.
Keywords: Pneumocystis jirovecii pneumonia; dose optimization; trimethoprim-sulfamethoxazole; co-trimoxazole

1. Introduction

Pneumocystis carinii pneumonia (PCP), also known as Pneumocystis jirovecii pneumonia has remained the most frequent and highly morbid fungal infection for patients with autoimmune disorders [1,2]. The incidence of PCP was more than 50% in immunocompromised patients, 22–45% in patients with hematological malignancy, 5–15% in transplant recipients and around 2% in patients with rheumatoid diseases [3,4]. The clinical indications of PCP, such as tachycardia, hypoxia, tachypnea, shortness of breath, etc., are the major causes of death of immunosuppressive patients [5]. Therefore, PCP is considered a hallmark disorder indicating human immunodeficiency virus (HIV) infection [5]. In the past few years, the occurrence or recurrence of PCP in HIV-positive patients has been reduced due to advanced technology and tools in diagnostic process, allowing early diagnosis; advanced management strategies in intensive care setting; and advanced preventive measures [6].

Co-trimoxazole is the combination of trimethoprim (TMP), which is a pyrimidine analog, and sulfamethoxazole (SMX), which is from the sulfonamide family [7]. TMP-SMX has been observed to substantially minimize the incidence of PCP in patients. There have been some published data on this topic. A retrospective study reported that the incidence of PCP and PCP-associated mortality was lower in patients with rheumatoid arthritis who received high-dose of glucocorticoids [8]. Another study reported that PCP developed in up to 40% of patients with the lymphoproliferative disease or acute lymphoblastic leukemia, and about 50% of patients experience hepatotoxicity [5]. Moreover, the incidence of adverse events (AEs) was decreased in non-HIV patients who received TMP-SMX prophylactically [9,10].

As with other antibiotics, TMP-SMX must be administered in an appropriate way to achieve adequate antimicrobial activity while reducing concentration-dependent toxicities, necessitating the avoidance of excessive dosage [11]. Specifically, in the era of antimicrobial resistance, optimal antibiotics usage is very crucial to ensure effectiveness of therapy [12]. The TMP-SMX dosing recommendations, on the basis of TMP component, is 320–640 mg/day, administered every 12 h, orally, to treat bacterial infections, and 15–20 mg/kg every 6 to 8 h intravenously then orally for the treatment of PCP infections [7].

In accordance with current dosing guidelines, the recommended therapy for PCP is high-dose TMP-SMX (TMP 15–20 mg/kg/day and SMX 75–100 mg/kg/day for 2–3 weeks) [13]. There is a high incidence of AEs in patients receiving recommended high doses of TMP-SMX. Due to insufficient data on the optimal dose of TMP-SMX, its use is limited. In randomized trials where various treatment regimen was compared for virus-associated PCP, patients receiving recommended high dose of TMP-SMX as a first-line treatment regimen had higher rates of AEs such as skin irritation (e.g., rashes), gastrointestinal disturbances, bone marrow suppression, renal impairment, hepatotoxicity as well as electrolyte disorder for which alternative treatment is required to avoid these AEs [14–17]. The therapeutic option for treatment of PCP requires a dose of ≥16 mg/kg of TMP-SMX with risk of hepato-renal AEs [18]. Therefore, to ensure the safety of TMP-SMX, there is a high demand to review current evidence in PCP patients with a focus on dose optimization strategies. Dose optimization is the key methods in antimicrobial stewardship programs and very effective to ensure therapeutic outcome of antimicrobial therapy as like in management of PCP [19,20].
2. Materials and Methods

2.1. Data Sources and Search Strategy

The systematic search assessing the dosing guidelines of TMP-SMX in patients was carried out using Preferred Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines [19,21]. Free-text web searches using Google Scholar, and databases such as PubMed, ScienceDirect, EMBASE, Scopus, the Cochrane Database for Systematic Reviews, etc., were explored for articles in English from January 2000 to December 2021. Reference lists of relevant studies were screened for additional titles for inclusion in the review. The keywords used for the search were "dose optimization", "Pneumocystis carinii pneumonia", "Pneumocystis jirovecii pneumonia", “HIV-patients”, “immune compromised patients” “Co-trimoxazole”, "trimethoprim/sulfamethoxazole”, and “TMP-SMX”.

2.2. Selection Criteria and Procedure

The studies reporting the dosing strategy of TMP-SMX in the patients for the occurrence or recurrence of PCP were included in this review. Based on the titles and abstracts, studies of all types with any data on clinical outcomes of TMP-SMX regimens were included for further screening. The retrospective studies, randomized controlled trials (RCTs), and case reports available in English were included in this study. The studies published before January 2000 or having inappropriate and incomplete information were excluded from the study. Titles and abstracts of all included articles collected through the search were screened by two reviewers independently. In case of uncertainty as to whether selected studies met inclusion criteria, they discussed with a third reviewer.

2.3. Data Extraction

Data extraction was performed using the predesigned data collection form for this review using Microsoft Word 2013. Information retrieved from the selected articles included author and year, design, sample size, characteristics of patients, dosing strategy, clinical outcomes, and findings. Data extraction was performed by one of the reviewers and reviewed by another co-author. Any discrepancies were resolved by a third reviewer.

2.4. Article Quality Assessment

The quality of each article was evaluated using a Newcastle–Ottawa Scale (NOS) for retrospective studies, Joanna Briggs Institute, The University of Adelaide (JBI, Adelaide, South Australia) critical checklist for case reports, and Cochrane bias tool for randomized clinical trials (RCTs) [22–24]. Two of the reviewers assessed the quality of each included study independently. They compared their results and disagreements were resolved by detailed discussion.

3. Results

3.1. Study Characteristics

In total, 857 related published studies were identified from grey literature as well as electronic databases. After the removal of the duplicate studies and other reasons, 163 studies were evaluated for eligibility criteria. Based on inclusion and exclusion criteria, 125 studies were excluded after the screening of the titles and abstracts. Most of the studies were identified through reference snowballing. Full-text articles were then screened for final analysis. Twenty-five articles were excluded due to the following reasons: no full-text (N = 09), literature reviews (N = 04), inappropriate intervention (N = 03), no required data (N = 03), and non-English (N = 06). A total of 13 articles met the inclusion criteria for final analysis [3,8,13,25–34]. Of the 13 selected studies, nine were retrospective cohort studies [8,13,25–30,34], two case reports [31] and two randomized controlled trial (RCT) [3,33]. The PRISMA flow diagram reporting the procedure of selection of studies is shown in Figure 1.
The studies collected were published after 2000. The main characteristics of selected studies were discussed in Table 1. A total of 2663 patients were recruited in the included studies.

Table 1. Dosing strategy of TMP-SMX in included studies.

| Author and Year | Design                     | Sample Size | Characteristics of Patients | Dosing Regimen                                      | Clinical Outcomes                                                                 | Findings                                                                 |
|-----------------|----------------------------|-------------|-----------------------------|-----------------------------------------------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Dao et al., 2014 [25] | Retrospective Cohort study | 305         | Patients with PCP infection | Group A received low-dose TMP-SMX regimen (TMP 0.15 mg/kg/day) while Group B received high-dose regimen (TMP 415 mg/kg/day) | In low-dose group, 32% of the patients were found to be within therapeutic range while in high-dose group, 22% of the patients were in therapeutic range | Furthers studies are required on large-scale to monitor plasma concentration of SMX and to evaluate the clinical outcomes. |
Table 1. Cont.

| Author and Year          | Design          | Sample Size | Characteristics of Patients               | Dosing Regimen                                                                 | Clinical Outcomes                                                                 | Findings                                                                 |
|--------------------------|-----------------|-------------|-------------------------------------------|-------------------------------------------------------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| Ohmura et al., 2018 [26] | Retrospective study | 81          | Patients with systemic rheumatoid diseases | Group A received low-dose SMX-TMP: ≤10 mg/kg/day; Group B received the intermediate dose, 10–15 mg/kg/day; Group C received high and conventional dose, 15–20 mg/kg/day for TMP dose. | The survival rate of Group A, B and C were 100%, 93.3%, and 96.7%, respectively. | Low-dose SMX/TMP treatment with ≤10 mg/kg/day for TMP was as safe and effective as high-dose regimen for occurrence and recurrence of PCP. |
| Yamashita et al., 2021 [27] | Retrospective study | 81          | Patients with HIV                         | Group A: standard-dose (≥6 SS (TMP-SMX 80 mg/400 mg tablets/week) Group B: low-dose groups (≤6 SS tablets/week). | PCP was not developed in any patients during study period | Low-dose TMP-SMX is optimal treatment option to treat and prevent PCP. |
| Schild et al., 2015 [13] | Observational Cohort study | 104         | Patients with PCPs in various immune dysfunctions | Patients received intermediate-dose TMP–SMX (TMP 10–15 mg/kg/day) and reduced to low-dose TMP–SMX (TMP 4–6 mg/kg/day) during therapy. | 23% of patients were switched to low-dose TMP–SMX in step-down group compared to intermediate dose group | A step-down strategy to low-dose TMP-SMX also reported to be effective and safe |
| Kosaka et al., 2017 [28] | Retrospective cohort study | 82          | Patients with non-HIV-PCP                 | Group A received conventional dose of TMP (15 to 20 mg/kg), Group B received a low dose of TMP <15 mg/kg | The mortality rates were 25.0% in conventional-dose group and 19.5% in low-dose groups | The low-dose regimen is well tolerated and results in fewer adverse effects. |
| Nakashima et al., 2018 [29] | Retrospective cohort study | 24          | Patients with non-HIV-PCP                 | Patients received low-dose TMP-SMX (TMP: 4≤10 mg/kg/day; SMX, 20–50 mg/kg/day and conventional dose TMP-SMX (TMP: 10–20 mg/kg/day; SMX: 50–100 mg/kg/day) was used as reference. | The total adverse reaction rate was 58.3% and 72.4% in low-dose group and conventional-dose group | Low-dose TMP-SMX may be considered as better treatment option for patients with non-HIV PCP. |
| Prasad et al., 2019 [30] | Retrospective study | 438         | Kidney transplant recipients             | SS dose of TMP-SMX OD, thrice daily and twice daily | The dose was reduced in 84 patients who experienced hyperkalemia and 102 patients who experienced leukopenia | TMP-SMX dose reduction is frequent in the first post-transplant year, but PCP does not occur. |
| Rehman et al., 2021 [31] | Case report      | 01          | Patient with CAP                          | -                                                                              | Respiratory condition improved on day 9 | Early diagnosis and management with TMP-SMX can lead to a better prognosis for patient |
| Lu et al., 2020 [32]     | Case report      | 01          | Patients with G6PD                        | TMP-SMZ (240/1200 mg) every 8 h, given IV. On day 16, PO (240/1200 mg) TID for 5 days | TMP-SMX reported to cause hemolysis in patients | Successfully treated with PCP with high dose of TMP-SMZ without any symptoms. |
| Park et al., 2021 [35]   | Retrospective cohort study | 1092        | Patients with PCP and rheumatoid arthritis | one SS tablet of TMP-SMX (400/80 mg) per day for prophylaxis | TMP-SMX reduced 1 year PCP incidence and related mortality | TMP-SMX prophylaxis significantly decreased the incidence of the PCP with a favorable safety profile in a patient with RA taking steroids. |
Table 1. Cont.

| Author and Year | Design   | Sample Size | Characteristics of Patients | Dosing Regimen                                                                 | Clinical Outcomes                                                                 | Findings                                                                                       |
|-----------------|----------|-------------|-----------------------------|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| Utsunomiya et al., 2017 [3] | RCT      | 183         | Patients with systemic Rheumatoid diseases | SS group (SMX-TMP of 400/80 mg daily). HS group (200/40 mg/day). ES group (initiated with 40/8 mg/day, increasing to 200/40 mg/day). | No cases of PCP were reported up to week 24                                                | The daily HS regimen is deemed to be first-line treatment option for the prophylaxis of PCP in patients with rheumatic disorders |
| Utsunomiya et al., 2020 [33] | RCT      | 183         | Patients with rheumatoid diseases | SS group (SMX-TMP 400/80 mg/day), HS group (200/40 mg/day). ES group (initiating at 40/8 mg/day and increasing to 200/40 mg/day). | PCP did not develop in any of the patients by week 52                                      | SMX-TMP 200 mg/40 mg might provide a favourable benefit-risk balance in PCP prophylaxis.       |
| Zamarlicha et al., 2015 [34] | Retrospective cohort study | 88         | Kidney transplant recipient | SMX-TMP dosed at 1 single-strength tablet thrice weekly | SMX-TMP therapy was discontinued in 10 patients while 11 patients received atovaquone. | A low-dose SMX-TMP regimen of 1 SS tablet thrice weekly is safe and effective.                 |

HIV = Human immunodeficiency virus; CAP = Community-acquired pneumonia; IV = intravenous; RCT = Randomized controlled trial; PCP = Pneumocystis jirovecii pneumonia; TMP-SMX = Trimethoprim-Sulfamethoxazole; TID = Three times a day. SS = Single strength; HS = Half strength; and ES; Escalation strength.

3.2. Quality Assessment of Studies

The outcomes of NOS, Cochrane Bias tool, and JBI critical checklist in the selected studies are summarized in Tables 2–4. Based on the NOS, eight studies were rated as a total score of 7, one study scored 6, and the remaining four studies scored 8. Overall, the score of included studies was 7. The Cochrane bias tool assessed that almost all the domains for RCT were at low risk of bias. As per the JBI critical checklist, the quality of case reports in both reports were of good quality.

Table 2. Quality assessment of cohort studies.

| Reference                             | Representative of Exposed Studies A | Selection of Non-Exposed B | Ascertainment of Exposure C | Demonstration of Outcome D | Comparability of Cohort Studies on Basis of Design E | Assessment of Outcomes F | Adequacy of Follow-up G | Quality Score |
|---------------------------------------|------------------------------------|---------------------------|----------------------------|---------------------------|------------------------------------------------------|--------------------------|--------------------------|--------------|
| Dao et al., 2014 [25]                 | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 8            |
| Ohmura et al., 2018 [26]              | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 7            |
| Yamashita et al., 2021 [27]           | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 7            |
| Schild et al., 2016 [13]              | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 7            |
| Kosaka et al., 2017 [28]              | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 7            |
| Nakashima et al., 2017 [29]           | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 7            |
| Prasad et al., 2019 [30]              | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 8            |
| Park et al., 2021 [35]                | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 8            |
| Zmarlicha et al., 2015 [34]           | *                                  | *                         | *                          | *                         | *                                                   | *                        | *                        | 8            |

A: * = truly representative or somewhat representative of average in target population. B: * = Drawn from the same community. C: * = Secured record or structured review. D: * = Yes, = No. E: * = Study controls for age, gender, and other factors. F: * = Record linkage or blind assessment, ** = Both. G: * = follow-up of all subjects.
Table 3. Risk of bias assessment for randomized controlled trials.

| Study                  | Random Sequence Generation | Allocation Concealment | Blinding of Participants and Personnel | Blinding of Outcome Assessment | Incomplete Outcome Data | Selective Reporting | Other Bias |
|------------------------|----------------------------|------------------------|---------------------------------------|------------------------------|-------------------------|---------------------|-----------|
| Utsunomiya et al., 2017 [3] | Low risk                  | Low risk               | Low risk                              | Low risk                     | Low risk                | Low risk            | Unclear   |
| Utsunomiya et al., 2020 [33] | Low risk                  | Low risk               | Low risk                              | Low risk                     | Unclear                 | Low risk            | Unclear   |

Table 4. Quality assessment of case reports.

| Questions * | Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Quality Rating |
|-------------|----|----|----|----|----|----|----|----|----------------|
| Rehman et al., 2021 [31] | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Good           |
| Lu et al., 2020 [32]     | Yes | Yes | Yes | Yes | Yes| Yes | Yes | Yes | Good           |

* JBI critical checklist.

3.3. Dosing Strategy of TMP-SMX in Selected Studies

Table 1 shows the dosing regimen of TMP-SMX and their clinical outcomes. Of 13 studies, four reported that patients having AIDS received TMP-SMX for prophylaxis, four reported patients with rheumatoid arthritis, two documented non-HIV patients, two reported kidney transplant recipients, and one reported the patient with G6PD deficiency. Of 13 studies, five compared the low-dose regimen of TMP-SMX with a high-dose regimen [25–29]. These studies documented that low-dose TMP-SMX therapy must be considered as a first-line treatment option to prevent occurrence and recurrence of PCP and PCP-associated AEs. However, Ohmura and his colleagues reported that a low-dose treatment regimen of TMP-SMX with <10 mg/kg/day for TMP was as well-tolerated and effective as high-dose therapy [26]. Similarly, Schild et al. reported that the patients received an intermediate-dose TMP-SMX (TMP 10–15 mg/kg/day) but later on, 23% of patients switched to low-dose TMP-SMX due to various AEs and this regimen was deemed to be safe and effective in patients with various immune dysfunctions [12].

Low-dose treatment regimens usually reported fewer side effects compared to the conventional dosing regimens. However, a study reported that in a total of 438 patients, the dose of TMP-SMX was reduced in 84 kidney transplant recipients for hyperkalemia, and 102 for leukopenia [30]. Another study reported side effects, such as hyperkalemia, with the use of TMP-SMX. Nakashima et al. reported that the total AEs rate was 58.3% in the low-dose group (TMP, 4–10 mg/kg/day; SMX 20–50 mg/kg/day), and in conventional-dose group (TMP, 10–20 mg/kg/day; SMX, 50–100 mg/kg/day), 72.4% of patients experienced AEs [29]. Similarly, another study reported that the mortality rates were lower in the low-dose group (19.5%) compared to the conventional-dose group (25.0%) [28]. A study documented that TMP-SMX was reported to cause hemolysis in patients with G6PD deficiency [32]. In both RCTs, no cases of PCP were documented up to weeks 24 and 52 [3,33].

4. Discussion

The main goal of this systematic review was to assess the current dosing strategy of TMP-SMZ to reduce the risk of PCP in patients especially those with various immunodeficiency syndromes. The impact of PCP on mortality and morbidity of the patients especially immunosuppressive patients is significant [36]. This review has revealed that low-dose TMP-SMX therapy should be the first-line treatment option, resulting in the reduction of mortality rate and PCP-associated AEs. The Cochrane meta-analysis reported that there was a decrease in the incidence of PCP up to 91% and decrease in mortality rate up to 83% when compared to the control group [9]. Although the TMP-SMX has been regarded as a first-line regimen for prophylaxis of PCP, it often has to be switched to second-line treatment such as dapsone, atovaquone, and atomized pentamidine due to TMP-SMX
associated AEs and drug intolerance caused by neutropenia and glucose-6-phosphate dehydrogenase (G6PD) deficiency [9,10,36].

Over the past few years, various preventive treatment options are available for opportunistic infections in immunocompromised and transplanted patients [37]. Although highly recommended by the healthcare community, prophylactic drugs are included in the crucial immunosuppressive regimen, resulting in considerable economic burden for the immunocompromised patients [38]. Routine PCP prophylaxis is recommended for patients treated in hospitals where the prevalence of PCP is at least 3% to 5% among immunocompromised patients [12,39,40]. Moreover, the risk of PCP among transplant recipients is greater in 1–6 month post-transplantation period, during prolonged neutropenia, or in patients receiving steroids, antilymphocyte antibodies, or calcineurin inhibitors [41]. Other predisposing factors include concomitant cytomegalovirus, infections, number of graft rejection episodes, and low CD4+ count lymphocyte counts [38]. A study reported that 27% of the kidney transplant recipients receiving TMP-SMX prophylactically with other medications experienced AEs such as cytopenia [42]. Therefore, routine prophylaxis is mainly required during the early post-transplant month and after therapy of rejection episodes. PCP prophylaxis is highly recommended in HIV-positive patients who have CD4+ counts less than 200 cells/mm$^3$ [43]. However, we failed to identify significant differences between the full-dose and low-dose regimen of TMP-SMX for the occurrence or recurrence of PCP. This strategy reduces economic burden of illness and enhances patients’ compliance to daily regimen plan.

Extrapolated from previous data, the first-line prophylactic agent is one single strength TMP-SMX tablet (TMP 80 mg/day; SMX 400 mg/day) or one double-strength (TMP 160 mg/day; SMX 800 mg/day) [44]. Alternative PCP prophylaxis includes one double-strength TMP-SMX tablet thrice per week, administration of dapsone either alone or in combination with leucovorin and pyrimethamine, atovaquone, or pentamidine sprays [44]. This practice may not provide desired clinical outcomes with the minimal risk of AEs. The double-strength seems to be effective while taken daily or thrice in a week, but daily administration of TMP-SMX prevents other post-transplant infectious diseases such as toxoplasmosis [45]. The standard dose of TMP-SMX was frequently used in an era before widespread solid organ transplantation and modern immunosuppressive treatment, which are now available for an ever-enlarging array of medical conditions [20,46].

Nowadays, patients with PCP differ from the patients that were treated 30–40 years ago [47]. The standard doses result in an absolute increase of 18% in the incidence of grade $\geq$3 AEs [46]. However, step-down therapy may be a worthy in exploring approaches to improve clinical outcomes [46]. The incidence of occurrence of PCP is the most frequent in patients with systemic rheumatoid arthritis disease taking steroids and immunosuppressive agents [26,48]. The risk factors for PCP in patients with rheumatoid disorders include age group (elderly > 65 years), use of glucocorticoids, and existing comorbidities [49]. In a study documenting the safety and efficacy of TMP-SMX given to patients with rheumatoid disorders taking high-dose steroids for PCP prophylaxis, the incidence of PCP and associated mortality rate was decreased after 1 year [35]. Moreover, another study showed that there were no proper guidelines on PCP prophylaxis in patients treated with immunosuppressive drugs, and high-dose steroids for immune-mediated dermatologic conditions [50]. Therefore, due to limited data on predictors and risk factors of PCP, the guidelines regarding PCP prophylaxis for various cohorts are also required in patients with rheumatological and other autoimmune dysfunctions [51].

This study does have several limitations. Firstly, the selected articles included patients from various countries, so the findings could have been affected by socio-demographic characteristics such as ethnicity, region, lifestyle, and environment. Secondly, the limited number of studies conducted after January 2000 forced us to include all studies that met inclusion criteria. Thirdly, although the quality of the majority of the included studies was good, due to small sample size, this may result in false-negative or false-positive findings.
5. Conclusions

These findings provided the current dosing strategy of TMP-SMX for the prevention and treatment of PCP. The low dose of TMP-SMX provides satisfactory outcomes while reducing the mortality rate and PCP-associated AEs. This strategy also reduces overall economic burden and enhances patients’ compliance to daily regimen plan. For some patient populations, such as PCP emerging on TMP-SMX prophylaxis in HIV-patients, it may still warrant to start prophylactic treatment regimen. Due to limited data available on the optimal dose of TMP-SMX, these findings would support the conduct of large-scale, prospective RCTs and cohort studies to provide guidelines regarding the dosing strategies for the PCP.

Author Contributions: Conceptualization, A.H., M.A.S.A. and Z.S.; methodology, W.A.A. and A.M.A. (Abdulrahman Mohammed Almontashri); review, S.A.B. and Z.S.; analysis, A.M.A. (Anas Mohammed Aljoaid), R.M.R. and B.M.A.; resources, M.A. and M.E.E.; writing—original draft preparation, A.M.A. (Anas Mohammed Aljoaid), R.M.R. and S.A.; supervision, M.E.E., M.A., S.A., A.J.M. and H.S.F.; funding acquisition, A.H. and M.A.S.A. All authors have read and agreed to the published version of the manuscript.

Funding: The authors would like to thank the Deanship of Scientific Research at Umm Al-Qura University for supporting this work by Grant Code: (22UQU429056DSR05).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data is available within the article.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Huang, L.; Cattamanchi, A.; Davis, J.L.; den Boon, S.; Kovacs, J.; Meshnick, S.; Miller, R.F.; Walzer, P.D.; Worodria, W.; Masur, H. HIV-associated Pneumocystis pneumonia. Proc. Am. Thorac. Soc. 2011, 8, 294–300. [CrossRef] [PubMed]
2. Thomas, C.F., Jr.; Limper, A.H. Pneumocystis pneumonia. N. Engl. J. Med. 2004, 350, 2487–2498. [CrossRef] [PubMed]
3. Utsunomiya, M.; Dobashi, H.; Odani, T.; Saito, K.; Yokogawa, N.; Nagasaka, K.; Takenaka, K.; Soejima, M.; Sugihara, T.; Hagiyama, H. Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: Results from a non-blinded, randomized controlled trial. Arthritis Res. Ther. 2017, 19, 7. [CrossRef] [PubMed]
4. Lee, S.H.; Huh, K.H.; Joo, D.J.; Kim, M.S.; Kim, S.I.; Lee, J.; Park, M.S.; Kim, Y.S.; Kim, S.K.; Chang, J.; et al. Risk factors for Pneumocystis jiroveci pneumonia (PJP) in kidney transplantation recipients. Sci. Rep. 2017, 7, 1571. [CrossRef]
5. Li, R.; Tang, Z.; Liu, F.; Yang, M. Efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of Pneumocystis pneumonia in human immunodeficiency virus-negative immunodeficient patients: A systematic review and meta-analysis. PLoS ONE 2021, 16, e0248524. [CrossRef]
6. White, P.L.; Price, J.S.; Backx, M. Therapy and management of Pneumocystis jiroveci infection. J. Fungi 2018, 4, 127. [CrossRef]
7. Autmizguine, J.; Melloni, C.; Hornik, C.P.; Dallefeld, S.; Harper, B.; Yogev, R.; Sullivan, J.E.; Atz, A.M.; Al-Uzri, A.; Mendley, S.; et al. Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children. Antimicrob. Agents Chemother. 2017, 62, e01813-17. [CrossRef]
8. Park, J.W.; Curtis, J.R.; Moon, J.; Song, Y.W.; Kim, S.; Lee, E.B. Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann. Rheum. Dis. 2018, 77, 644–649. [CrossRef]
9. Hughes, W.T.; Feldman, S.; Aur, R.J.; Verzosa, M.S.; Hustu, H.O. Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonia. Cancer 1975, 36, 2004–2009. [CrossRef]
10. Nazir, H.F.; Elshinawy, M.; AlRawas, A.; Khat, D.; Zadjaly, S.; Wali, Y. Efficacy and Safety of Dapsone Versus Trimethoprim/Sulfamethoxazole for Pneumocystis jiroveci Prophylaxis in Children with Acute Lymphoblastic Leukemia with a Background of Ethnic Neutropenia. J. Pediatr. Hematol. Oncol. 2017, 39, 203–208. [CrossRef]
11. Brown, G.R. Cotrimoxazole—Optimal dosing in the critically ill. Ann. Intensive Care 2014, 4, 13. [CrossRef] [PubMed]
12. Alhifany, A.A.; Alqurashi, A.F.; Al-Agamy, M.H.; Alkhushaym, N.; Alhomoud, F.; Alhomoud, F.K.; Almangour, T.A. Employment of mapping technology in antimicrobial resistance reporting in Saudi Arabia. Geospatial Health 2020, 15, 1. [CrossRef]
13. Creemers-Schild, D.; Kroon, F.P.; Kuijper, E.J.; de Boer, M.G.J. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: Lessons from an observational cohort study. *Infection* 2016, 44, 291–299. [CrossRef]

14. Sattler, F.R.; Cowan, R.; Nielsen, D.M.; Ruskin, J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome: A prospective, non crossover study. *Ann. Intern. Med.* 1988, 109, 280–287. [CrossRef] [PubMed]

15. Medina, I.; Mills, J.; Leoung, G.; Hopewell, P.C.; Lee, B.; Modin, G.; Benowitz, N.; Wosky, C.B. Oral therapy for *Pneumocystis carinii* pneumonia in the acquired immunodeficiency syndrome: A controlled trial of trimethoprim—Sulfamethoxazole versus trimethoprim—Dapsone. *N. Eng. J. Med.* 1990, 323, 776–782. [CrossRef] [PubMed]

16. Klein, N.C.; Duncanson, F.P.; Lenox, T.H.; Foszpaniak, C.; Sherer, C.B.; Quenstel, H.; Nunez, M.; Suarez, M.; Kawwaff, O.; Pitta-Alvarez, A. Trimethoprim-sulfamethoxazole versus pentamidine for *Pneumocystis carinii* pneumonia in AIDS patients: Results of a large prospective randomized treatment trial. *AIDS* 1992, 6, 301–305. [CrossRef]

17. Safrin, S.; Finkelstein, D.M.; Feinberg, J.; Frame, P.; Simpson, G.; Wu, A.; Cheung, T.; Soiero, R.; Hojczyk, P.; Black, J.R. Comparison of three regimens for treatment of mild to moderate *Pneumocystis carinii* pneumonia in patients with AIDS: A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. *Ann. Intern. Med.* 1996, 124, 792–802. [CrossRef]

18. Chang, H.-M.; Tsai, H.-C.; Lee, S.S.-J.; Kunin, C.; Lin, P.-C.; Wann, S.-R.; Chen, Y.-S. High daily doses of trimethoprim-sulfamethoxazole are an independent risk factor for adverse reactions in patients with *Pneumocystis pneumonia and AIDS*. *J. Chin. Med. Assoc.* 2016, 79, 314–319. [CrossRef]

19. Haseeb, A.; Faidah, H.S.; Alghamdi, S.; Aloitaib, A.F.; Elrongal, M.E.; Mahrous, A.J.; Almarzouky Abuussaisn, S.S.; Obaid, N.A.; Alghamdi, M.; AlQarni, A. Dose Optimization of Colistin: A Systematic Review. *Antibiotics* 2021, 10, 1454. [CrossRef]

20. Klein, N.C.; Duncanson, F.P.; Lenox, T.H.; Forszpaniak, C.; Sherer, C.B.; Quentzel, H.; Nunez, M.; Suarez, M.; Kawwaff, O.; Alghamdi, S. Evaluation of Antimicrobial Stewardship Programs (ASPs) and their perceived level of success at Makah region hospitals, Kingdom of Saudi Arabia. *Saudi Pharm. J.* 2020, 28, 1166–1171. [CrossRef]

21. Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst. Rev.* 2015, 4, 1–9. [CrossRef]

22. Wells, G.; Connell, D.; Peterson, J.; Lee, S.S.; Wu, A.; Cheung, T.; Soiero, R.; Hojczyk, P.; Black, J.R. Comparison of three regimens for treatment of mild to moderate *Pneumocystis carinii* pneumonia in patients with AIDS: A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. *Ann. Intern. Med.* 1996, 124, 792–802. [CrossRef]

23. Higgins, J.P.; Savovic, J.; Page, M.J.; Elbers, R.G.; Sterne, J.A. Assessing risk of bias in a randomized trial. *Cochrane Database Syst. Rev.* 2019, 205–228. [CrossRef]

24. Ma, L.-L.; Wang, Y.-Y.; Yang, Z.-H.; Huang, D.; Weng, H.; Zeng, X.-T. Methodological quality (risk of bias) assessment tools for primary and secondary medical studies: What are they and which is better? *Mil. Med. Res.* 2020, 7, 7. [CrossRef]

25. Dao, B.D.; Barreto, J.N.; Wolf, R.C.; Dierkhising, R.A.; Plevak, M.F.; Tosh, P.K. Serum peak sulfamethoxazole concentrations demonstrate difficulty in achieving a target range: A retrospective cohort study. *Curr. Ther. Res.* 2014, 76, 104–109. [CrossRef]

26. Ohmura, S.-I.; Naniwa, T.; Tamechika, S.-Y.; Miyamoto, T.; Shichi, D.; Kazawa, N.; Iwagaitsu, S.; Maeda, S.; Wada, J.-I.; Niimi, A. Effectiveness and safety of lower dose sulfamethoxazole/trimethoprim therapy for *Pneumocystis jirovecii* pneumonia in patients with systemic rheumatic diseases: A retrospective multicenter study. *BMC Infect. Dis.* 2019, 25, 253–261. [CrossRef]

27. Yamashita, K.; Shimomura, Y.; Ikesue, H.; Mouri, N.; Yoshimoto, A.; Hashida, T. Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of *Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: A retrospective observational study. J. Infect. Chemother.* 2021, 21, 664. [CrossRef]

28. Kosaka, M.; Ushiki, A.; Ikuyama, Y.; Hirai, K.; Matsuo, A.; Hachiya, T.; Hanaoka, M. A four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of *Pneumocystis pneumonia in patients without HIV infection. Antimicrob. Agents Chemother.* 2017, 61, e01173-17. [CrossRef]

29. Nakashima, K.; Aoshima, M.; Nakashita, T.; Hara, M.; Otsuki, A.; Noma, S.; Misawa, M.; Otsuka, Y.; Motojima, S. Low-dose trimethoprim-sulfamethoxazole for *Pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: A single-center retrospective observational cohort study. J. Microb. Immunol. Infect.* 2018, 51, 810–820. [CrossRef]

30. Prasad, G.R.; Beckley, J.; Mathur, M.; Gunasekaran, M.; Nash, M.M.; Rapi, L.; Huang, M.; Zaltzman, J.S. Safety and efficacy of prophylaxis for *Pneumocystis jirovecii pneumonia involving trimethoprim-sulfamethoxazole dose reduction in kidney transplantation. BMC Infect. Dis.* 2019, 1, 1–7. [CrossRef]

31. Rehman, U.; Farhan, K.; Shahnawaz, W.; Khalid, M.Z.; Neupane, K.J.C. A Rare Case of *Pneumocystis Pneumonia in HIV Patient on Glucocorticoid. Cureus* 2021, 13, e14445. [CrossRef]

32. Lu, Y.-W.; Chen, T.-C. Use of trimethoprim-sulfamethoxazole in a patient with G6PD deficiency for treating *Pneumocystis jirovecii pneumonia without haemolysis: Case report and literature review. J. Clin. Pharmacol. Ther.* 2020, 45, 1483–1485. [CrossRef]

33. Usunomiya, M.; Dobashi, H.; Odani, T.; Saito, K.; Yokogawa, N.; Nagasaka, K.; Takenaka, K.; Soejima, M.; Sugihara, T.; Hagiyama, H. An open-label, randomized controlled trial of trimethoprim-sulfamethoxazole–trimethoprim for *Pneumocystis prophylaxis: Results of 52-week follow-up. Rheumatol. Adv. Pract.* 2020, 4, rkaa029. [CrossRef] [PubMed]

34. Zmarlicka, M.; Martin, S.T.; Cardwell, S.M.; Nailor, M.D. Tolerability of low-dose sulfamethoxazole/trimethoprim for *Pneumocystis jirovecii pneumonia prophylaxis in kidney transplant recipients. Prog. Transplant.* 2015, 25, 210–216. [CrossRef]
35. Park, J.W.; Curtis, J.R.; Kim, M.J.; Lee, H.; Song, Y.W.; Lee, E.B. *Pneumocystis* pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—Clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazole. *Arthritis Resp. Ther.* 2019, 21, 207. [CrossRef]

36. Maschmeyer, G.; Helweg-Larsen, J.; Pagano, L.; Robin, C.; Cordonnier, C.; Schellongowski, P.; on behalf of the 6th European Conference on Infections in Leukemia (ECIL-6), a joint venture of The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN). ECIL guidelines for treatment of *Pneumocystis jirovecii* pneumonia in non-HIV-infected haematology patients. *J. Antimicrob. Chemother.* 2016, 71, 2405–2413. [CrossRef]

37. Schmajuk, G.; Jafri, K.; Evans, M.; Shiboski, S.; Gianfrancesco, M.; Izadi, Z.; Patterson, S.L.; Aggarwal, I.; Sarkar, U.; Dudley, R.A. *Pneumocystis jirovecii* pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. in *Seminars in arthritis and rheumatism*. *Semin. Arthritis Rheum.* 2019, 48, 1087–1092. [CrossRef]

38. Di Cocco, P.; Orlando, G.; Bonanni, L.; D’Angelo, M.; Clemente, K.; Greco, S.; Gravante, G.; Madeddu, F.; Scelzo, C.; Famulari, A. A systematic review of two different trimetoprim–sulfamethoxazole regimens used to prevent *Pneumocystis jirovecii* and no prophylaxis at all in transplant recipients: Appraising the evidence. *Transplant. Proc.* 2009, 41, 1201–1203. [CrossRef]

39. Sadiq, U.; Shrestha, U.; Guzman, N. *Prevention of Opportunistic Infections in HIV*; StatPearls Publishing: Treasure Island, FL, USA, 2020.

40. Haseeb, A.; Faidah, H.S.; Mount, P.F.; Mahony, A.; Trubiano, J.A. Taking the challenge: A protocolized approach to optimize *Pneumocystis* pneumonia prophylaxis in renal transplant recipients. *Am. J. Transplant.* 2018, 18, 462–466. [CrossRef]

41. Martin, S.; Fishman, J.; the AST Infectious Diseases Community of Practice. *Pneumocystis* pneumonia in solid organ transplantation. *Am. J. Transplant.* 2013, 13, 272–279. [CrossRef]

42. Urbancic, K.F.; Ierino, F.; Phillips, E.; Mount, P.F.; Mahony, A.; Trubiano, J.A. Prevention of Opportunistic Infections (OI) in Patients with HIV Infection. *JAIDS J. Acquir. Immune Defic. Syndr.* 2021, 12, 38–45.

43. Rodriguez, M.; Fishman, J.A. Prevention of infection due to *Pneumocystis* spp. in human immunodeficiency virus-negative immunocompromised patients. *Clin. Microbiol. Rev.* 2004, 17, 770–782. [CrossRef]

44. Butler-Laporte, G.; Smyth, E.; Amar-Zifkin, A.; Cheng, M.P.; McDonald, E.G.; Lee, T.C. *Pneumocystis jirovecii* Pneumonia: A Systematic Review and Meta-analysis. In *Open Forum Infectious Diseases*; Oxford University Press: Oxford, UK, 2020.

45. Harriga, M.; Koike, R.; Miyasaka, M. *Pneumocystis* pneumonia associated with infliximab in Japan. *N. Engl. J. Med.* 2007, 357, 1874–1876. [CrossRef]

46. Katsuyama, T.; Saito, K.; Kurokawa, M.; Tsuchiya, K.; Watanabe, T.; Koga, Y.; Nakanishi, M.; Nagamura, Y.; Inoue, M.; Ito, K. Prophylaxis for *Pneumocystis* pneumonia in patients with rheumatoid arthritis treated with biologics, based on risk factors found in a retrospective study. *Arthritis Res. Ther.* 2014, 16, R43. [CrossRef]

47. Lehman, J.S.; Gonzalez Santiago, T.M.; Wetter, D.A.; Kalaaji, A.N.; Limper, A.H. Weighing the risks and benefits of *Pneumocystis* pneumonia prophylaxis in iatrogenically immunosuppressed dermatology patients. *Int. J. Dermatol.* 2017, 56, e5–e6. [CrossRef]

48. Wolfe, R.M.; Peacock, J.E., Jr. *Pneumocystis* Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented? *Curr. Rheumatol. Rep.* 2017, 19, 35. [CrossRef]